Elsevier

The Lancet

Volume 372, Issue 9639, 23–29 August 2008, Pages 608-610
The Lancet

Comment
Declining breast cancer incidence and decreased HRT use

https://doi.org/10.1016/S0140-6736(08)61255-6Get rights and content

First page preview

First page preview
Click to open first page preview

References (18)

  • DM Parkin et al.

    Global cancer statistics, 2002

    CA Cancer J Clin

    (2005)
  • K Canfell et al.

    Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia

    Med J Aust

    (2008)
  • K Kerlikowske et al.

    Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population

    J Natl Cancer Inst

    (2007)
  • PM Ravdin et al.

    The decrease in breast-cancer incidence in 2003 in the United States

    N Engl J Med

    (2007)
  • M Johnston

    Breast cancer drop linked to fall in use of HRT. New Zealand Herald

  • EV Kliewer et al.

    A decline in breast-cancer incidence

    N Engl J Med

    (2007)
  • A Katalinic et al.

    Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy

    Breast Cancer Res Treat

    (2008)
  • H Allemend et al.

    Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend

    Bull Can

    (2008)
  • Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer

    Lancet

    (1997)
There are more references available in the full text version of this article.

Cited by (106)

  • Estrogenic and anti-inflammatory effects of pseudoprotodioscin in atherosclerosis-prone mice: Insights into endothelial cells and perivascular adipose tissues

    2020, European Journal of Pharmacology
    Citation Excerpt :

    However, little was known regarding to the precise pharmacological effects of saponins compounds involved. More importantly, the beneficial effect of hormone replacement therapy on the cardiovascular system of postmenopausal women has been contested for the detrimental side effects of its clinical use, which include ovarian and breast cancers (Kumle, 2008). Thus, PPD, with previously reported anti-tumor properties (Dong et al., 2001), is a promising agent which exhibits potential clinical therapeutic effects on estrogen deficiency-associated atherosclerosis, such as that in postmenopausal women.

  • Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor

    2018, Clinical Breast Cancer
    Citation Excerpt :

    Owing to the increasing usage of mammography screening and menopausal hormones, the BC incidence rates increased significantly in the 1980s and 1990s.3,4 After 2002, with the decreased usage of menopausal hormones,5 the BC rate decreased, especially in white women and for hormone receptor-positive (HR+) BC.6,7 In the United States, the overall 5-year relative survival rate improved from 75.1% in 1975 to 1977 to 90.0% in 2001 to 2007.8

  • Osteoporosis

    2015, Endocrinology: Adult and Pediatric
View all citing articles on Scopus
View full text